Nivolumab Misses Mark in Japanese Patients With Platinum-Resistant Ovarian Cancer

Nivolumab did not significantly improve overall survival compared with chemotherapy in Japanese patients with platinum-resistant ovarian cancer. Nivolumab (Opdivo) did not significantly improve overall survival (OS) compared with chemotherapy in Japanese patients with platinum-resistant ovarian cancer, missing the primary end point of the phase 3 NINJA trial (JapicCTI-153004).1. Results,...